Prescott Group Capital Management L.L.C. Purchases New Position in IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• Prescott Group Capital Management has acquired a new investment in IQVIA Holdings, purchasing 5,900 shares valued at approximately $1,040,000.
• IQVIA reported earnings of $2.81 EPS for the last quarter, exceeding predictions of $2.77, with quarterly revenue of $4.02 billion, surpassing expectations of $3.96 billion.
• Analysts have set a consensus price target of $226.95 for IQVIA, with a majority rating it as a "Moderate Buy".

Prescott Group Capital Management L.L.C. acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 5,900 shares of the medical research company's stock, valued at approximately $1,040,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. American National Bank & Trust bought a new position in shares of IQVIA in the 1st quarter valued at $26,000. Golden State Wealth Management LLC increased its stake in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares during the last quarter. AllSquare Wealth Management LLC bought a new stake in IQVIA during the 1st quarter worth $33,000. ST Germain D J Co. Inc. grew its position in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares during the last quarter. Finally, GKV Capital Management Co. Inc. bought a new stake in IQVIA during the 4th quarter worth $39,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on IQV shares. Mizuho set a $225.00 price objective on IQVIA and gave the stock an "outperform" rating in a research report on Friday. Hsbc Global Res lowered IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Cowen restated a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. UBS Group boosted their price objective on IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Finally, Robert W. Baird boosted their price objective on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Seven investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $228.62.

IQVIA Stock Performance

Shares of IQVIA stock traded down $3.47 during trading hours on Tuesday, reaching $194.30. The company had a trading volume of 1,096,574 shares, compared to its average volume of 2,036,073. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The business has a fifty day simple moving average of $158.18 and a 200 day simple moving average of $169.99. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market cap of $33.03 billion, a PE ratio of 28.12, a price-to-earnings-growth ratio of 2.18 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The firm's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company earned $2.64 earnings per share. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.